Apogee Therapeutics, Inc. APGE
We take great care to ensure that the data presented and summarized in this overview for Apogee Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in APGE
Top Purchases
Top Sells
About APGE
Insider Transactions at APGE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 31
2025
|
Michael Thomas Henderson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+0.64%
|
$187,000
$22.86 P/Share
|
|
Jan 08
2025
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,000
-0.57%
|
$735,000
$49.05 P/Share
|
|
Jan 02
2025
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,085
-0.53%
|
$191,995
$47.18 P/Share
|
|
Jan 02
2025
|
Carl Dambkowski Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,360
+0.52%
|
$29,920
$22.86 P/Share
|
|
Dec 12
2024
|
Mark C. Mc Kenna Director |
BUY
Open market or private purchase
|
Direct |
20,000
+44.23%
|
$980,000
$49.43 P/Share
|
|
Dec 11
2024
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,540
-0.87%
|
$222,460
$49.31 P/Share
|
|
Dec 11
2024
|
Carl Dambkowski Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,815
+0.69%
|
$39,930
$22.86 P/Share
|
|
Dec 04
2024
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,000
-0.56%
|
$690,000
$46.84 P/Share
|
|
Dec 04
2024
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,665
-2.49%
|
$306,590
$46.07 P/Share
|
|
Nov 06
2024
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,000
-0.55%
|
$885,000
$59.55 P/Share
|
|
Nov 06
2024
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,665
-1.22%
|
$393,235
$59.43 P/Share
|
|
Oct 02
2024
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,000
-1.44%
|
$2,240,000
$56.41 P/Share
|
|
Oct 02
2024
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,665
-1.19%
|
$373,240
$56.51 P/Share
|
|
Sep 04
2024
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,000
-1.4%
|
$1,880,000
$47.75 P/Share
|
|
Sep 04
2024
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,665
-1.16%
|
$313,255
$47.78 P/Share
|
|
Aug 23
2024
|
Jane Henderson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,000
-2.9%
|
$288,000
$48.26 P/Share
|
|
Aug 07
2024
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,000
-0.91%
|
$1,640,000
$41.36 P/Share
|
|
Aug 07
2024
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,335
-0.83%
|
$300,735
$41.37 P/Share
|
|
Jul 05
2024
|
Michael Thomas Henderson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,000
-1.01%
|
$555,000
$37.26 P/Share
|
|
Jul 03
2024
|
Carl Dambkowski Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,995
-1.0%
|
$221,815
$37.73 P/Share
|
Last 12 Months Summary
Buy / Acquisition
87.6K
Shares
From
4
Insiders
| Other acquisition or disposition | 55.9K shares |
|---|---|
| Open market or private purchase | 20K shares |
| Exercise of conversion of derivative security | 11.7K shares |
Sell / Disposition
291K
Shares
From
4
Insiders
| Other acquisition or disposition | 55.9K shares |
|---|---|
| Open market or private sale | 235K shares |